Immuron Reports Steady Sales Growth for Travelan®, Its OTC Immune Supplement. Immuron announced solid revenue growth for the first half of its 2026 fiscal year, ending December 31, 2025. Global sales were AUD$4.2 million, a 5% increase over H1 FY:25 revenue. By region, sales in Australia grew 13% to AUD$3.3 million and sales in the USA grew 17% to AUD$0.9 million over the prior year’s period, while sales in Canada decreased 85% to AUD$56 thousand. Revenue drivers included increased awareness through digital and social media marketing initiatives, as well as in-store promotions and increased Southeast Asian travel. We believe that commercial traction, coupled with the launch of Immuron’s new ProIBS® product in December 2025, will support further growth and stock price appreciation from current levels.
